We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$16.6B
AUM Growth
+$2.17B
Cap. Flow
-$81M
Cap. Flow %
-0.49%
Top 10 Hldgs %
31.47%
Holding
166
New
39
Increased
28
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
ARMK icon
Aramark
ARMK
+$366M
2
XLNX
Xilinx Inc
XLNX
+$332M
3
RTX icon
RTX Corp
RTX
+$299M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$289M
5
AVGO icon
Broadcom
AVGO
+$243M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$498M
2
INFO
IHS Markit Ltd. Common Shares
INFO
+$299M
3
ABBV icon
AbbVie
ABBV
+$298M
4
PANW icon
Palo Alto Networks
PANW
+$217M
5
BMY icon
Bristol-Myers Squibb
BMY
+$215M

Sector Composition

Rank Sector Weight
1 Healthcare 38.27%
2 Communication Services 13.23%
3 Financials 10.05%
4 Technology 9.85%
5 Industrials 8.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRMK
51
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$73.1M 0.44%
7,170,213
– –
KSU
52
DELISTED
Kansas City Southern
KSU
$72.3M 0.44%
354,400
-39,600
-10% -$7.44M
EFX icon
53
Equifax
EFX
$21.4B
$71.5M 0.43%
370,684
-25,800
-7% -$4.34M
KRTX
54
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$71.1M 0.43%
700,000
– –
KYNB
55
Kyntra Bio
KYNB
$29.4M
$70.5M 0.42%
76,000
+2,000
+3% +$2.1M
BCAB icon
56
BioAtla
BCAB
$5.74M
$66.9M 0.4%
+39,341
New +$65.8M
GBIO
57
DELISTED
Generation Bio
GBIO
$64.3M 0.39%
226,882
+14,819
+7% +$4.76M
ARNA
58
DELISTED
Arena Pharmaceuticals Inc
ARNA
$57.6M 0.35%
750,000
+120,114
+19% +$9M
PACB icon
59
Pacific Biosciences
PACB
$370M
$54.5M 0.33%
2,100,000
-1,963,770
-48% -$33.4M
CYTK icon
60
Cytokinetics
CYTK
$10.4B
$49.9M 0.3%
2,400,000
+250,000
+12% +$4.57M
PTGX icon
61
Protagonist Therapeutics
PTGX
$9.44B
$48.9M 0.29%
2,425,000
-325,000
-12% -$6.99M
ALNY icon
62
Alnylam Pharmaceuticals
ALNY
$29.3B
$45.5M 0.27%
350,000
-850,000
-71% -$113M
ZGNX
63
DELISTED
Zogenix, Inc.
ZGNX
$45M 0.27%
2,250,000
– –
CLGX
64
DELISTED
Corelogic, Inc.
CLGX
$44.4M 0.27%
574,028
+229,028
+66% +$17.1M
AGIO icon
65
Agios Pharmaceuticals
AGIO
$1.93B
$43.3M 0.26%
1,000,000
-83,429
-8% -$3.3M
IONS icon
66
Ionis Pharmaceuticals
IONS
$9.4B
$42.4M 0.26%
+750,000
New +$37.4M
ANNX icon
67
Annexon
ANNX
$886M
$39M 0.23%
1,557,261
-100,000
-6% -$2.57M
RDUS
68
DELISTED
Radius Health, Inc.
RDUS
$37.6M 0.23%
2,107,400
– –
TVRD
69
Tvardi Therapeutics
TVRD
$23.4M
$37.3M 0.22%
68,472
+5,972
+10% +$3.13M
LNTH icon
70
Lantheus
LNTH
$6.59B
$35.7M 0.22%
2,650,000
– –
ZYME icon
71
Zymeworks
ZYME
$1.67B
$35.4M 0.21%
750,000
-102,200
-12% -$4.75M
KRYS icon
72
Krystal Biotech
KRYS
$9.66B
$31.5M 0.19%
525,000
+50,000
+11% +$2.5M
NVAX icon
73
Novavax
NVAX
$1.31B
$30.7M 0.18%
+275,000
New +$29.2M
NUVB icon
74
Nuvation Bio
NUVB
$2.32B
$29.3M 0.18%
+2,500,000
New +$26M
FOLD
75
DELISTED
Amicus Therapeutics
FOLD
$28.9M 0.17%
+1,250,000
New +$25.6M
1 2
3
4 5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Farallon Capital Management held 166 positions worth $16.6B, up 15% from $14.5B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Farallon Capital Management's Q4 2020 filing shows 39 new, 28 increased, 33 reduced and 30 closed positions. Its largest new stake was Aramark: 15,268,169 shares worth $424M. The largest sale was Immunomedics Inc, an estimated $498M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 41% a quarter earlier, followed by Communication Services and Financials.

  • Farallon Capital Management's largest Q4 2020 buy was Aramark: 15,268,169 shares worth $424M.
  • Farallon Capital Management added most to Willis Towers Watson in Q4 2020, an estimated $188M increase.
  • Farallon Capital Management's biggest Q4 2020 reduction was AbbVie, cutting an estimated $298M.
  • Farallon Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $498M.
  • Farallon Capital Management's ten largest holdings make up 31% of its $16.6B portfolio in Q4 2020.
  • Farallon Capital Management opened 39 new positions and closed 30 in Q4 2020.
  • Farallon Capital Management's portfolio value rose 15% quarter-over-quarter to $16.6B.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.